이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

3SBio 과거 수익 실적

과거 기준 확인 2/6

3SBio은 연평균 13%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 증가했으며, 연간 11.7%였습니다. 매출은 연평균 10%의 비율로 증가했습니다. 3SBio의 자기자본이익률은 9.6%이고 순이익률은 19.8%입니다.

주요 정보

13.0%

수익 성장률

14.0%

EPS 성장률

Biotechs 산업 성장	11.0%
매출 성장률	10.0%
자기자본 수익률	9.6%
순이익	19.8%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

3SBio 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SHSC:1530 수익, 비용 및 수입 (CNY Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	7,816	1,549	3,487	795
30 Sep 23	7,686	1,739	3,351	750
30 Jun 23	7,549	1,929	3,205	705
31 Mar 23	7,204	1,922	3,085	699
31 Dec 22	6,866	1,916	2,974	694
30 Sep 22	6,618	1,817	2,849	699
30 Jun 22	6,369	1,719	2,725	703
31 Mar 22	6,376	1,685	2,710	729
31 Dec 21	6,382	1,651	2,696	754
30 Sep 21	6,191	1,342	2,688	717
30 Jun 21	6,000	1,032	2,681	681
31 Mar 21	5,794	934	2,577	636
31 Dec 20	5,588	836	2,472	590
30 Sep 20	5,479	1,095	2,535	581
30 Jun 20	5,370	1,355	2,598	571
31 Mar 20	5,344	1,164	2,612	549
31 Dec 19	5,318	974	2,627	527
30 Sep 19	5,185	1,029	2,409	549
30 Jun 19	5,053	1,084	2,190	572
31 Mar 19	4,818	1,181	2,099	468
31 Dec 18	4,584	1,277	2,008	363
30 Sep 18	4,393	1,167	1,911	181
30 Jun 18	4,202	1,057	1,814	0
31 Mar 18	3,968	996	1,731	0
31 Dec 17	3,734	935	1,648	0
30 Sep 17	3,467	877	1,601	0
30 Jun 17	3,199	818	1,555	0
31 Mar 17	2,998	766	1,437	0
31 Dec 16	2,797	713	1,318	0
30 Sep 16	2,492	642	1,104	0
30 Jun 16	2,188	571	889	0
31 Mar 16	1,930	548	800	0
31 Dec 15	1,673	526	710	0
30 Sep 15	1,503	456	676	0
30 Jun 15	1,364	341	744	0
31 Mar 15	1,247	316	673	0
31 Dec 14	1,131	292	602	0
30 Sep 14	1,044	238	581	0
31 Dec 13	875	96	439	0
30 Sep 13	842	95	432	-54

양질의 수익: 1530 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: 1530 의 현재 순이익 이익률 (19.8%) 작년보다 낮습니다 (27.9%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 1530 의 수입은 지난 5년 동안 매년 13% 씩 증가했습니다.

성장 가속화: 1530 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: 1530 은 지난 1년 동안 마이너스 수익 성장( -19.1% )을 기록하여 Biotechs 업계 평균( 22.1% ).

3SBio 과거 수익 실적

과거 기준 확인 2/6

주요 정보

최근 과거 실적 업데이트

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.40 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Full year 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.65 in FY 2021)

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

Recent updates

3Sbio Inc. Announces Management Changes

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Mandi Foam of 3SBio Inc. Approves for Market Launch

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.40 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.65 in FY 2021)

Now 22% undervalued

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

3SBio Inc., Annual General Meeting, Jun 22, 2022

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

3SBio Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

3Sbio Inc. Announces Completion the Enrolment of Subjects for Phase Ii Clinical Study

New 90-day high: HK$8.42

3SBio Inc. Provides Update on License Agreement with AstraZeneca and Hongkong Sansheng

New 90-day high: HK$7.81

New 90-day low: HK$7.06

3Sbio Inc. Receives Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212

New 90-day low: HK$7.19

New 90-day low: HK$8.13

First half earnings released

New 90-day low: HK$8.22

3SBio Inc. to Report First Half, 2020 Results on Aug 17, 2020

New 90-day low - HK$8.98

First half earnings released

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기